Background: To demonstrate reduced risk from reversing left ventricular hypertrophy (LVH) in hypertension, one must show that it is independent of blood pressure reduction.
Methods and Results: A feasibility study was conducted with 15 patients. The study employed 48-hour Holter recording, exercise treadmill (for ST-segment changes) and, as nec essary, thallium scintigraphy and coronary angiography. All patients were treated for 3 months with quinapril (10 mg) and demonstrated decreased mean arterial pressure (125 ± 3.1 vs 103 ± 1.9 mmHg; P < .01) and left ventricular mass index (125 ± 6.4 vs 104 ± 4.9; P < .02) with preserved left ventricular function. There were no significant changes in these patients with moderate LVH in the incidence of arrhythmias; however, 4 of the 15 patients developed ST-segment changes prior to LVH reversal, and these changes did not recur in 3 patients following reversal of LVH or when pressure was allowed to rise.
Conclusions: Ischemic changes, rather than development of arrhythmias, may be of greater value in demonstrating risk reduction with LVH reversal. Nloreover, these preliminary data suggest pitfalls in demonstrating risk reduction after LVH reversal, indicating that more sen sitive and adequate techniques are necessary to show risk reduction from LVH.
Levy D., Garrison RJ, Savage DD, Kannel WB, Castelli WPPrognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med322:1561, 1990
2.
Frohlich EDLeft ventricular hypertrophy: An independent factor of risk. In Frohlich ED, Brest AN (eds.). Preventive Aspects of Coronary Heart Disease. Cardiovascular Clinics. FA Davis Company, Philadelphiu , pp. 816-894, 1990
3.
Dellsperger KC, Marcus HLEffects of left ventricular hypertrophy on the coronary circulation. Am J Cardiol65:1504. 1990
4.
Houghton JLCarr AA, Prisant LM, Rogers WB, von Dohlcn TW, Flowers NC, Frank MJMorphologic. hemodynamic and coronary perfusion characteristics in severe left ventricular hypertrophy secondary to systemic hypertension and evidence for nonatherosclerotic myocardial ischemia. Am J Cardiol69:219, 1992
5.
Szlachcic J. , Tubau J., O'Kelly B.Ammon S.Daiss K., Massie B.What is the role of silent coronary artery disease and left ventricular hypertrophy in the genesis of ventricular arrhythmias in men with essential hypertension? J Am Coll Cardiol19:803, 1992
6.
Devereux RB, Roman MJInterrelationships between hypertension, left ventricular hypertrophy and coronary heart disease. J Hypertens11(Suppl 4):3, 1993
7.
Frohlich EDCurrent issues in hypertension: Old questions with new answers and new questions . Med Clin North Am76:1043, 1992
8.
Dahlof B., Pennert RJ, Hansson L.Reversal of left ventricular hypertrophy in hypertensive patients: A meta analysis of 109 treatment studies. Am J Hypertens5:95, 1992
9.
Frohlich ED, Apstein C., Chobanian A., Devereux RB, Dustan HP, Dzau V., Fauad-Tarazi F., Horan MJ, Marcus M., Massie B., Pfeffer MA, Re RN, Roccella EJ, Savage D., Shub C.The heart in hypertension. N Engl J Med327:998, 1992
10.
Dunn FG, Pringle SDSudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy. J Hypertens11:1003, 1993
11.
Frohlich EDIs reversal of left ventricular hypertrophy in hypertension beneficial?Hypertension18 (Suppl I):133, 1991
12.
Dunn FG, Ventura HO, Messerli FH, Kobrin I., Frohlich EDTime course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation76:254, 1987
13.
Schulman SP , Weiss JL, Becker LC, Gottlieb SO, Woodruff KM, Wersfeldt ML, Gerstenblith G.The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med322:1350, 1990
14.
B., De TrimarcoLuca N, Ricciardelli B, Rosiello G, Volpe M, Condorelli G, Lembo G, Condorelli M. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol62:745, 1988
15.
Frohlich ED , Sasaki O., Chien Y., Arita M.Changes in cardiovascular mass, left ventricular pumping ability and aortic distensibility after calcium antagonists in Wistar-Kyoto and spontaneously hypertensive rats. J Hypertens10:1369, 1992
16.
Frohlich ED , Sasaki O.Dissociation of changes in cardiovascular mass and performance with angiotensin converting enzyme inhibitors in Wistar-Kyoto and spontaneously hypertensive rats. J Am Coll Cardiol16:1492, 1990
17.
Sahn D., DeMaria A.Kisslo J., Weyman A.Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation58:1072, 1978
18.
Troy BL, Pombo J., Rackley CEMeasurement of left ventricular wall thickness and mass by echocardiography . Circulation45:602, 1972
19.
Teicholz LE. Krculen T., Herman AV, Gorlin R.Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asyncrgy. Am J Cardiol37:7, 1976
20.
Devereux RB , Alonso DR, Lutas EM, Gottlieb G., Campo E. Sachs I, Reichek N.Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol57:450, 1986
21.
Borow KM, Green LH, Grossman W., Brawnwald E.Left ventricular end-systolic stress-shortening and stress-length relationships in humans. Am J Cardiol50:1031, 1982
22.
Colan SD, Borow KM, Neumann A.Left ventricular end-systolic wall stress-velocity of fiber shortening relation: A load-independent index of myocardial contractility. J Am Coll Cardiol4:715, 1984
23.
Messerli FH , de Carvalho JGR.Christie B, Frohlich ED. Systemic and regional hemodynamics in low, normal and high cardiac output in borderline hypertension. Circulation58:441, 1978
24.
Appleton CP , Hatle LK, Popp RLRelation of transmitral flow velocity patterns to left ventricular diastolic function: New insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol12:426, 1988
25.
Grossman E. , Oren S., Garavaglia GE, Messerli FH, Frohlich EDSystemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension. Circulation78:1394, 1988
26.
Frohlicher VF , Marconder EDManual of Exercise Testing. Year Book Medical Publishers, Chicago, 1987
27.
Glantz SAPrimer of Biostatistics, 3rd ed. McGraw-Hill, New York, 1992
28.
Zehender M. , Martinez T., Hohnloser S., Geibel A., Gerish U., Olschewski M., et al. Prevalence of circadian variation and spontaneous variability of cardiac disorders and ECG changes suggestive of myocardial ischemia in systemic arterial hypertension. Circulation85:1808, 1992
29.
Yurev AP, deQuattro V., Devereux RBHypertensive heart diseases: Relationship of silent ischemia to coronary artery disease and left ventricular hypertrophy. Am Heart J120: 928, 1990
30.
Antony I., Nitenberg A, Foult JM, Aptecar E. Coronary Vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy . J Am Coll Cardiol22:514, 1993
31.
Brush J., Faxon DP, Salmon S., Jacobs AK, Ryan TJAbnormal endothelium-dependent coronary vasomotion in hypertensive patients . J Am Coll Cardiol19:809, 1992
32.
Ghali JK, Kadakia S., Cooper RS, Liao Y.Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary heart disease. J Am Coll Cardiol17:1277, 1991
33.
Strauer BEDevelopment of cardiac failure by coronary small vessel disease in hypertensive heart disease?J Hypertens9 (Suppl 2):11, 1991
34.
Weber KT, Brilla CGPathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation83:1849, 1991
35.
Ventura H., Frohlich ED, Messerli FH, Kobrin I., Kardon MBCardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension . Am J Cardiol55:1023, 1985
36.
Ando K., Frohlich ED, Chien Y., Pegram BLEffects of quinapril on systemic and regional hemodynamics and cardiac mass in spontaneously hypertensive and Wistar-Kyoto rats. J Vasc Med Biol3:117, 1991
37.
Chien Y., Frohlich ED, Kardon M., Hunter J., Pegram B.Coronary physiological flow reserve during treadmill exercise is prevented in spontaneously hypertensive rats. [Abstr] Circulation86 (Suppl I):330, 1992
38.
Kaneko K., Susic D., Frohlich ED, Nunez E.Losartan reduces cardiac mass independent of pressure and coronary hemodynamic changes. (in press)
39.
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.The 1992 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). Arch Intern Med153:154, 1993
40.
Scheler S., Motz W., Strauer B.Mechanisms of angina pectoris in patients with systemic hypertension and normal epicardial coronary arteries by arteriogram. Am J Cardiol73:478, 1994
